The findings suggest that TRIM56-regulated post-translational modifications may contribute to glioma development through stabilization of cIAP1 and that TRIM56 may serve as a novel prognostic indicator and therapeutic molecular target for GBM. The gene discussed is TRIM56; the disease is central nervous system cancer.